The control group will receive usual multidisciplinary care without a WHO. Prior to consenting, parents will understand that a child entering the study with a prescribed WHO and allocated to the control group will cease wearing it. Parents and children will be advised there is debate about effectiveness; the study will generate evidence to inform future practice. They will also be informed that children in either group could lose ROM during the trial period as this is the natural history of CP, and because of this, their child will be monitored closely throughout the 3 year study period.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.